Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Malignant Tumor of Pancreas Metastatic to Liver 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 6Methotrexate 5Radiotherapy 4Carboplatin 4Magnetic Resonance Spectroscopy 3Vincristine 2Thiotepa 2Specimen Handling 2Procarbazine 2Nivolumab 2Filgrastim 2Carmustine 2Bevacizumab 2sodium thiosulfate 1selinexor 1sargramostim 1motexafin gadolinium 1irinotecan sucrosofate 1infigratinib 1fluoroacetic acid 1Trastuzumab 1Topotecan 1Standard of Care 1Rituximab 1Radiation 1RG7388 1Psychiatric Rehabilitation 1Practice Guidelines as Topic 1Peripheral Blood Stem Cell Transplantation 1Oxaloacetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Central Nervous System Neoplasms × irinotecan sucrosofate × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡